Diabetes & Endocrinology Clinical Trials Update: Week 23, 2026

Published June 5, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert. Blog posts are AI-drafted from ClinicalTrials.gov source data and reviewed by the editorial team. See our editorial policy for details.

A Study of Orforglipron for the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-MAINTAIN)

This Phase 3 trial tested an oral medication called orforglipron to see if it can help adults with obesity or overweight keep weight off after they have lost it. The study included 376 participants in the US and Puerto Rico who had previously used injectable weight-loss treatments. If this medicine works well, it might offer a simpler pill option for maintaining weight loss instead of injections.

STEP TEENS Weight Maintenance: A Research Study on How Well Semaglutide Helps Teenagers With Excess Body Weight to Lose Weight and Maintain Weight Loss

This ongoing Phase 4 study is looking at semaglutide, a weekly injection, to help teenagers with obesity lose weight and keep it off over the long term. The trial involves 500 young people across several countries and lasts for at least three years. Successful results could provide a new way to manage obesity in adolescents with a treatment designed for lasting support.

Weight Gain Prevention in Adolescents and Young Adults

This Phase 3 trial, planned by the University of Minnesota, aims to prevent unhealthy weight gain in healthy adolescents and young adults through a combination of medication and lifestyle coaching. Though still not recruiting, this study hopes to enroll 140 participants. If successful, it could introduce new early interventions to reduce the risk of obesity before it develops.

A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Who Observe Ramadan Fasting

This Phase 3 study is testing orforglipron to see if it is safe and effective for adults with type 2 diabetes who fast during Ramadan. The study is recruiting participants in countries including India and Saudi Arabia and will last up to 48 weeks. Positive findings could give people who fast a new option for managing blood sugar without interrupting their religious practices.

A Trial of Setmelanotide in Acquired Hypothalamic Obesity

This Phase 3 trial is focused on people aged 4 and older with acquired hypothalamic obesity, a rare condition causing severe weight gain. The drug setmelanotide is being tested to see if it can reduce both weight and hunger over a year-long study with 143 participants worldwide. A successful outcome may provide a new treatment for this difficult-to-manage form of obesity.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.